ProKidney to Attend Major Healthcare Conference
ProKidney to Participate in Major Healthcare Conference
ProKidney Corp. (Nasdaq: PROK), a leading late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), has announced that senior management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference. This significant event will take place from September 4 to September 6, 2024.
Details of the Conference Participation
During the conference, the ProKidney management team will engage in discussions regarding the company’s advancements and the potential impact of their novel therapies in the management of CKD. This includes a fireside chat scheduled for September 5, 2024, at 7:00 a.m. ET.
Accessibility of Live Webcast
The live webcast from the event will be available in the 'Events' section of the Investor Relations tab on ProKidney's official website. Following the fireside chat, a replay of the webcast will be accessible for 90 days, providing broader access to their insights and updates.
One-on-One Meetings with Investors
In addition to the group presentations, ProKidney's management will also hold one-on-one meetings with interested investors during the event. Investors wishing to arrange a meeting are encouraged to reach out through their Morgan Stanley representatives.
About ProKidney Corp.
Founded in 2015, ProKidney is recognized for its pioneering work in treating chronic kidney disease through innovative cellular therapies. The company’s lead candidate, rilparencel, also known as REACT, represents a breakthrough in autologous cellular therapy aimed at preserving kidney function in patients affected by diabetes and advanced CKD. Rilparencel has attained Regenerative Medicine Advanced Therapy (RMAT) designation, alongside guidance from key regulatory bodies such as the FDA and EMA, reinforcing its ongoing Phase 3 clinical program.
Contact Information for Investors
For inquiries regarding investment opportunities and conference participation, interested parties may contact:
ProKidney
Ethan Holdaway
Email: Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Email: Daniel@lifesciadvisors.com
Frequently Asked Questions
What is the significance of ProKidney's participation in the conference?
ProKidney's participation highlights their commitment to sharing advancements in therapies for chronic kidney disease with potential investors and stakeholders.
Where can I access the live webcast during the conference?
The live webcast will be available on ProKidney's official website under the Investor Relations section.
What is rilparencel and its importance?
Rilparencel, or REACT, is a patented autologous therapy in clinical trials aimed at preserving kidney function in patients with diabetes and advanced CKD.
How can investors schedule one-on-one meetings?
Investors interested in one-on-one meetings should contact their Morgan Stanley representatives for scheduling details.
How long will the replay of the webcast be available after the event?
The replay of the webcast will be available for a period of 90 days after the initial broadcast.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- EVgo and Trump Media: Latest Post-Market Stock Reactions
- NorthStar Medical Radioisotopes Engages in Industry Summit
- Vir Biotechnology's Upcoming Engagements and Innovations in Healthcare
- Tradeswomen Conference Unites Female Iron Workers in a Major Event
- Brian Scott Takes the Helm as CFO and COO at AMN Healthcare
- New Insights on Targeting Toxic Gain of Function Mutations
- Impact of Healthcare Costs on American Voting in 2024
- NASA's New Astrophysics Missions Set to Unlock Cosmic Mysteries
- SWK Holdings Corporation Faces Board Change as Pennington Resigns
- Starbucks Takes Bold Steps Towards a Sustainable Coffee Future
Recent Articles
- Fancamp Partners with Lode Gold to Enhance Mineral Assets
- Avicanna Secures Patent for Innovative Topical Cannabinoid Technology
- Cartier Resources Reports High-Grade Gold Intersections
- Abcourt Mines Reports High-Grade Gold Intersections
- Bread Financial™ to Engage at Barclays Financial Services Conference
- CERIS Innovations in Fraud Prevention Solutions
- Archrock Completes HSR Act Waiting Period for Acquisition
- SEALSQ Corp Innovations in Quantum-Resistant Digital Wallets
- Investing Insights into Berkshire Hathaway's Performance
- Investing in Current Stock Market Giants
- Ozempic's Impact on Novo Nordisk: Recent Findings
- Mural Oncology to Join Major Investor Conferences
- European Wax Center to Speak at Piper Sandler Conference
- EyePoint Pharmaceuticals Prepares for Investor Conferences
- Super Hi Reports Strong Q2 2024 Financial Results
- Invivyd's PEMGARDA™ Shows 84% Risk Reduction in COVID-19
- Supremex Launches First Environmental, Social and Governance Report
- Fox Factory's Commitment to Sustainability in 2023
- Clearside Biomedical Completes Final Participant Visit in ODYSSEY Trial
- Advancements in the Cosmetic Peptide Synthesis Market
- Vacuum Evaporation Boat Market Expected Growth to $4.1 Billion
- Skydance Media to Acquire Paramount Global Amid Bidding War
- Solar Coca-Cola Boosts Delivery Efficiency with Descartes
- Palo Alto Networks: AI and Cybersecurity Leadership
- Alliance Trust PLC Reports Latest Net Asset Value Insights
- Scotiabank Reports Drop in Q3 Profit Amid Credit Loss Provisions
- Iovance Biotherapeutics: A Path to Growth with Amtagvi
- Market Update: Investors Eye Nvidia's Earnings
- Aircraft Ground Support Equipment Market Growth Insights
- 3D Printing Glasses Market Growth Forecast
- Underground Mining Equipment Market Growth Forecast
- Laser Gas Analyzer Market Set to Reach $5.39 Billion by 2034
- Cheer Holding Secures Patent for AI Data Management System
- Parsons Announces Lead Engineering Role on Toll Lane Project
- Kronos Advanced Technologies to Acquire Suarez Corporation
- Disclosure of Interests by Rathbones Group Plc
- Key Disclosure by Rathbones Group Plc in Keywords Studios Plc
- Discover Wall Street's Top Dividend Stocks
- Top Stocks to Consider Ahead of Fed Rate Cuts
- Three AI Stocks Competing with Nvidia's Growth
- Epoxy Curing Agents Market Forecast to Reach USD 10.1 Billion
- Bitumen Market Projections: USD 116 Billion by 2034
- Toughened Glass Market Growth Forecast to Reach USD 94.6 Billion
- Calibre Enhances Gold Exploration Results at Pan Mine
- Jiayin Group Inc. Reports Strong Q2 2024 Financial Results
- Matrix Service Company Announces Fourth Quarter Financial Call
- Record High Household Debt in Canada: Insights and Implications
- LanzaTech's Upcoming Investor Events Engagement
- Liberty Bank, N.A. Opens New Branch in Millbrae Community
- JD.com Unveils $5 Billion Share Repurchase Initiative